We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

IVD Cancer Diagnostic Products to be Based on Microarrays

By HospiMedica staff writers
Posted on 05 Sep 2007
Microarray-based tests will enable clinicians to provide more efficient and complete methods to diagnose, classify, and manage patients suffering from cancer.

Affymetrix, Inc. More...
(Santa Clara, CA, USA) and Ipsogen have signed a Powered by Affymetrix (PbA) agreement, which gives Ipsogen (Marseilles, France) non-exclusive access to Affymetrix microarray technology to develop and market in vitro diagnostic (IVD) tests, initially for breast cancer, on a worldwide basis. The PbA agreement enables Ipsogen to incorporate Affymetrix arrays into its diagnostic products.

Ipsogen is a molecular diagnostic company focused on the development and commercialization of innovative diagnostic products to guide treatment options in cancers. "Ipsogen's strong expertise in delivering high medical value IVD products in the field of blood cancers will be leveraged together with our new PbA capabilities to expedite the launch of a range of innovative and unique IVD tests for guiding breast cancer therapies,” said Vincent Fert, president and CEO of Ipsogen.

"The microarray-based tools and applications in the Powered by Affymetrix program continue to accelerate the discovery and development of oncology diagnostics products,” said Noel Doheny, senior vice president, Molecular Diagnostics at Affymetrix. "This is the era of personalized medicine and we are pleased that another innovator in the molecular diagnostic field like Ipsogen has adopted our proven technology platform.”


Related Links:
Affymetrix
Ipsogen

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: 123RF

Existing Cardiovascular Risk Calculators Predict Several Common Cancers

Cardiovascular risk calculators are embedded in primary and secondary care to estimate 10‑year risk of heart attack or stroke from factors such as age, body mass index, and smoking. Many of these same... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.